41 related articles for article (PubMed ID: 37949483)
1. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma.
Ilanchezhian M; Jha A; Pacak K; Del Rivero J
Curr Treat Options Oncol; 2020 Aug; 21(11):85. PubMed ID: 32862332
[TBL] [Abstract][Full Text] [Related]
2. Effects of Peptide Receptor Radiotherapy in Patients with Advanced Paraganglioma and Pheochromocytoma: A Nation-Wide Cohort Study.
Kornerup LS; Andreassen M; Knigge U; Arveschoug AK; Poulsen PL; Kjær A; Oturai PS; Grønbæk H; Dam G
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611027
[TBL] [Abstract][Full Text] [Related]
3. High-Specific-Activity 131I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma.
Al-Ward R; Brondani VB; Sawani S; Potter CL; Xu G; Waguespack SG; Varghese J; Habra MA; Lu Y; Jimenez C
Clin Nucl Med; 2024 Apr; ():. PubMed ID: 38630996
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib for Metastatic Progressed Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data.
Tian R; Yao X; Song J; Wang J; Fu J; Shi L; Yu F; Zhang P; Zhang C; Ni Y; Wang F
J Endocr Soc; 2024 Apr; 8(6):bvae061. PubMed ID: 38650712
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of SDHB pathogenic variant carriers: A systematic review and meta-analysis.
Davidoff DF; De Abreu Lourenco R; Tsang VHM; Benn DE; Clifton-Bligh RJ
J Clin Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38605204
[TBL] [Abstract][Full Text] [Related]
6. Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement.
Taïeb D; Nölting S; Perrier ND; Fassnacht M; Carrasquillo JA; Grossman AB; Clifton-Bligh R; Wanna GB; Schwam ZG; Amar L; Bourdeau I; Casey RT; Crona J; Deal CL; Del Rivero J; Duh QY; Eisenhofer G; Fojo T; Ghayee HK; Gimenez-Roqueplo AP; Gill AJ; Hicks R; Imperiale A; Jha A; Kerstens MN; de Krijger RR; Lacroix A; Lazurova I; Lin FI; Lussey-Lepoutre C; Maher ER; Mete O; Naruse M; Nilubol N; Robledo M; Sebag F; Shah NS; Tanabe A; Thompson GB; Timmers HJLM; Widimsky J; Young WJ; Meuter L; Lenders JWM; Pacak K
Nat Rev Endocrinol; 2024 Mar; 20(3):168-184. PubMed ID: 38097671
[TBL] [Abstract][Full Text] [Related]
7. Metastatic pheochromocytoma and paraganglioma.
Angelousi A; Kassi E; Zografos G; Kaltsas G
Eur J Clin Invest; 2015 Sep; 45(9):986-97. PubMed ID: 26183460
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.
Tong A; Li M; Cui Y; Ma X; Wang H; Li Y
Front Endocrinol (Lausanne); 2020; 11():61. PubMed ID: 32132978
[No Abstract] [Full Text] [Related]
9. Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study.
Fischer A; Kloos S; Remde H; Dischinger U; Pamporaki C; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Bechmann N; Hantel C; Mohr H; Pellegata NS; Bornstein SR; Kroiss M; Auernhammer CJ; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
Eur J Endocrinol; 2023 Nov; 189(5):546-565. PubMed ID: 37949483
[TBL] [Abstract][Full Text] [Related]
10. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of systemic treatment according to germline mutational status in patients with metastatic pheochromocytoma and paraganglioma.
Park YG; Park I; Kim Y; Lee HS; Lee W; Yoon S; Lee JL
Clin Genitourin Cancer; 2024 Apr; 22(2):413-419. PubMed ID: 38228412
[TBL] [Abstract][Full Text] [Related]
12. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
13. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
[TBL] [Abstract][Full Text] [Related]
14. Combined Treatment With 131I-MIBG and Sunitinib Induces Remission in a Patient With Metastatic Paraganglioma Due to Hereditary Paraganglioma-Pheochromocytoma Syndrome From an SDHB Mutation.
Makis W; McCann K; McEwan AJ; Sawyer MB
Clin Nucl Med; 2016 Mar; 41(3):204-6. PubMed ID: 26359568
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
